Clinical Trials Sponsored by Kari Kendra

Total 858 results

Kari Kendra

Recruiting

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Kari Kendra
Karyopharm Therapeutics Inc

Completed

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (KPT-330)

Recurrent Melanoma

United States
Kari Kendra
Eli Lilly and Company

Completed

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Breast Cancer

United States
Fresenius Kabi Japan

Completed

Trial of 6% HES130/0.4

Hemorrhage | Hypovolemia

Japan
Kari Alyse Leibowitz

Completed

Stanford Clinics Physician Mindset Training

Hypertension | Diabetes Mellitus | Diabetes | Overweight and Obesity | Pre Diabetes

United States
Fresenius Kabi Japan

Completed

Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery

Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage

Japan
Fresenius Kabi

Not yet recruiting

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Malnutrition | Pediatric ALL | Essential Fatty Acid Deficiency | Parenteral Nutrition Associated Liver Disease (PNALD)
Fresenius Kabi

Not yet recruiting

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Malnutrition | Malnutrition, Child

United States
AKARI Therapeutics

Recruiting

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Thrombotic Microangiopathies

United States, United Kingdom, Poland
Fresenius Kabi

Completed

Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care

Critical Illness | Nutrition Therapy

Russian Federation
AKARI Therapeutics

Withdrawn

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) (ARREST-BP)

Bullous Pemphigoid

United States, Germany, Netherlands, Poland
Fresenius Kabi

Terminated

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

Malnutrition, Child

United States
Fresenius Kabi

Terminated

Quality of Care of Oncological Patients With HPN (VHPE-S)

Tumors and Home Parenteral Nutrition

Germany
AKARI Therapeutics

Completed

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Bullous Pemphigoid (BP)

Germany, Netherlands
Fresenius Kabi

Completed

Three-Chamber Bags Retrospective Study in Spain

Parenteral Nutrition | Blood Stream Infection

Spain
AKARI Therapeutics

Completed

Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 (CAPSTONE)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Kazakhstan, Lithuania, Sri Lanka
Fresenius Kabi

Withdrawn

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

Malnutrition

United States
Fresenius Kabi

Completed

Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2

Austria
Fresenius Kabi

Completed

Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)

Chronic Kidney Disease

China
Fresenius Kabi

Completed

Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects

Healthy

Canada
Fresenius Kabi

Completed

VolulyteTM in Cardiac Surgery

Heart; Dysfunction Postoperative, Cardiac Surgery

Canada
Fresenius Kabi

Completed

Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis (CRYSTMAS)

Sepsis

France, Germany
Fresenius Kabi

Completed

Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)

Diabetic Nephropathy

China
Fresenius Kabi

Completed

Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery

Rectal Tumors

Netherlands
Fresenius Kabi

Completed

Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery

Enteral Nutrition Regimen Prior to Surgery

United Kingdom
Endra Lifesciences

Not yet recruiting

Comparison of MRI-PDFF to TAEUS FLIP Device to Estimate Liver Fat Fraction in Adults

Steatosis of Liver

Germany
AKARI Therapeutics

Enrolling by invitation

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms (CONSENTII)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States
Fresenius Kabi

Completed

A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response (OPALE)

Rheumatoid Arthritis | Psoriasis | Crohn Disease | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis

France
Fresenius Kabi

Withdrawn

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Malnutrition | Pediatric ALL | Neurocognitive Deficit | Parenteral Nutrition Associated Liver Disease | Essential Fatty Acid Deficiency
AKARI Therapeutics

Terminated

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Atopic Keratoconjunctivitis (AKC)

United Kingdom
Fresenius Kabi

Terminated

Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy

Cancer-related Malnutrition

France
Fresenius Kabi

Completed

Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet

Chronic Kidney Disease

Hungary
Fresenius Kabi

Completed

Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers

Blood Glucose

Germany
Fresenius Kabi

Completed

Screening Day Latin America

Malnutrition | Nutritional Status | Caloric Deficit

Colombia, Brazil, Mexico, Ecuador, Peru, Chile, Argentina, Panama
Fresenius Kabi

Terminated

Fluid Resuscitation in Patients Suffering From Burns Injury

Burns

United Kingdom
Fresenius Kabi

Completed

Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients

Diabetes

Germany
Fresenius Kabi

Completed

Voluven® in Paediatric Patients

Cardiac Surgery | Cardiopulmonary Bypass

Austria, Belgium
Fresenius Kabi

Terminated

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients

Cancer | Cachexia

Italy, Poland
Fresenius Kabi

Completed

The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients

Enteral Nutrition

Germany
Fresenius Kabi

Terminated

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

Intraoperative Complications

China
Fresenius Kabi

Completed

Preoperative Oral Nutritional Supplement (preOP Booster) in Visceral Surgery

Enteral Nutrition (Food for Special Medical Purposes)

Italy
Fresenius Kabi

Completed

Study to Evaluate the Effect of Hydroxyethyl Starch (HES) in Complications of Patients After Abdominal Surgery

Postoperative Complications

China
Fresenius Kabi

Not yet recruiting

bIosimilar of aDalimumab, an European evAluation (IDEA)

Rheumatoid Arthritis | Crohn Disease | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis
Fresenius Kabi

Completed

Chronic Kidney Disease Observational Database - Taiwan (CKDOD)

Chronic Kidney Insufficiency

Taiwan
Fresenius Kabi

Terminated

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days

United States
AKARI Therapeutics

Terminated

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (CONSERVE)

Paroxysmal Nocturnal Hemoglobinuria

Poland
Fresenius Kabi

Terminated

Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness

Critical Illness

France, Germany, Poland
Fresenius Kabi

Completed

Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-027-CNI)

Chronic Kidney Disease

Russian Federation
Fresenius Kabi

Completed

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

Chronic Obstructive Pulmonary Disease | Chronic Heart Failure | Cachexia

Germany, Poland
Fresenius Kabi

Completed

Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake

Malnutrition

Germany

3

Subscribe